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Abstract:  
Background: Diffuse intrinsic pontine glioma (DIPG) is a lethal type of pediatric brain tumor that is 
resistant to conventional chemotherapies. Palbociclib is a putative novel DIPG treatment that restricts 
the proliferation of rapidly dividing cancer cells via selective inhibition of cyclin-dependent kinase 
(CDK) 4 and CDK6. However, implementing palbociclib as a monotherapy for DIPG is unfeasible, as 
CDK4/6 inhibitor resistance is commonplace and palbociclib does not readily cross the blood-brain 
barrier (BBB) or persist in the CNS. We aimed to use palbociclib to inhibit growth of DIPG cells, in 
combination with the rapamycin analogue temsirolimus, which is known to ameliorate resistance to 
CDK4/6 inhibitors and inhibit BBB efflux.   
Materials and methods: We tested palbociclib and temsirolimus in three patient-derived DIPG cell 
lines. The expression profiles of key proteins in the CDK4/6 and mammalian target of rapamycin 
(mTOR) signaling pathways were assessed, respectively, to determine feasibility against DIPG. We 
also investigated effects on cell viability and examined in vivo drug toxicity.  
Results: Immunoblot analyses revealed palbociclib and temsirolimus inhibited CDK4/6 and mTOR 
signaling, through canonical perturbation of phosphorylation of the retinoblastoma (RB) and mTOR 
proteins, respectively, while we also observed non-canonical downregulation of mTOR by palbociclib. 
We demonstrated that palbociclib and temsirolimus inhibited cell proliferation in all three DIPG cell 
lines, acting synergistically in combination to further restrict cell growth. Flow cytometric analyses 
revealed both drugs caused G1 cell cycle arrest and clonogenic assays showed non-reversible effects 
on cell proliferation. Palbociclib did not elicit neurotoxicity in primary cultures of normal rat hippocampi 
or when infused into rat brains.  
Conclusion: These data illustrate the in vitro antiproliferative effects of CDK4/6 and mTOR inhibitors 
in DIPG cells. Direct infusion of palbociclib into the brain, in combination with systemic delivery of 
temsirolimus, represents a promising new approach to developing a much-needed treatment for 
DIPG. 
Keywords: Palbociclib, temsirolimus, brain tumor, DIPG, retinoblastoma protein, cyclin-dependent 
kinase    
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Introduction 
Diffuse intrinsic pontine glioma (DIPG) is a lethal high-grade pediatric glioma that accounts for 
up to 85% of all brainstem gliomas.1 Approximately 100-150 new cases of DIPG in children are 
recorded each year in the USA.2 The genetic basis of DIPG is complex and several genetic and 
epigenetic alterations are associated with the disease. However, approximately 80% of DIPG tumors 
exhibit the missense mutation lysine 27 to methionine (K27M) in the genes that encode histones H3.1 
and H3.3 (H3.1K27M and H3.3K27M, respectively).3 DIPG is difficult to treat due to the heterogeneity 
generated from the various mutations associated with the disease, as well as its sensitive location in 
the brainstem. Fractionated radiation is the conventional treatment but has no long-term benefit, with 
the two-year survival rate currently below 20%.1 Chemotherapies have also proved ineffective and 
new treatments are urgently required. The results of combinatorial approaches utilizing synergistic 
targeted therapies have been encouraging.3  
Palbociclib (also known as PD-0332991) is a selective inhibitor of cyclin-dependent kinases 
(CDK) 4 and 6.4 Both CDK4 and 6 form functionally identical heterodimeric complexes with cyclin D1 
(cycD1), cycD2 or cycD3, which phosphorylate and inactivate retinoblastoma protein (RB).5 
Inactivation of RB relieves negative regulation of the E2F transcription factor, which facilitates 
progression through the G1/S transition in the cell cycle, permitting DNA synthesis and cell 
proliferation. Palbociclib inhibits the kinase activity of CDK4/6, thereby preventing phosphorylation of 
RB and cell cycle progression. This leads to cell cycle arrest in the G1 phase of the cell cycle. Thus, 
treatment with palbociclib results in cells accumulating in G1 and inhibition of cell proliferation. 
However, malignancies can develop resistance to CDK4/6 inhibitors,6 putatively via cycD1 expression 
flux, with down-regulation of the mammalian target of rapamycin (mTOR) representing one approach 
to abrogate this.4  
Temsirolimus (previously known as CCI-779) is an ester analogue, or rapalogue, of the 
mTOR inhibitor rapamycin, which possesses increased aqueous solubility and improved 
pharmacokinetics compared to its parent molecule.7 Temsirolimus is antitumorigenic in vitro through 
targeted inhibition of the mTORC1 complex and was approved for intravenous systemic delivery for 
the treatment of renal cell carcinoma in 2007.8 The effectiveness of temsirolimus as a single agent 
therapy against other types of cancer has been limited,9 though it has shown some capacity to treat 
glioblastoma10 and has been shown to readily cross the blood-brain barrier (BBB).11 Temsirolimus 
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combination therapies are currently being trialed for treatment of central nervous system (CNS) 
tumors, where it has been found to be well tolerated by patients and appears amenable to 
combination with other targeted therapies.12 
We used three cell lines encompassing both archetypal DIPG histone mutations (H3.1K27M 
found in SU-DIPG IV cells and H3.3K27M found in SF7761 and SF8628 cells) to demonstrate that by 
selectively disrupting the CDK4/6-cycD1-RB and mTOR signaling pathways, sustained inhibition of 
DIPG cell proliferation can be achieved through synergistic cytostatic-driven effects on cell growth, 
increasing the therapeutic potential of these two candidate DIPG therapeutics.   
 
Material and methods 
Reagents were purchased from ThermoFisher Scientific (Loughborough, UK) unless 
otherwise stated. Palbociclib and temsirolimus were purchased from Selleckchem (Houston, Texas, 
USA). Drug synergy analysis, based on cell viability assays, compared single-agent treatments to 
equivalent combination treatments, as previously described.13 Statistical analyses were performed 
using GraphPad Prism 6 and MiniTab 17. All values are expressed as mean of triplicate 
determinations ± SEM. Values of p < 0.05 were considered statistically significant.  
Cell culture and cell treatments 
Patient-derived SF7761 and SF8628 cell lines were isolated from DIPG tumor tissue acquired 
by the University of California San Francisco (UCSF) Tissue Bank. SU-DIPG IV cells were isolated 
from a DIPG patient at Stanford University. All procedures were conducted with Institutional Review 
Board approval. SF7761 and SF8628 cells were obtained from Nalin Gupta (UCSF) and SU-DIPG IV 
from Michelle Monje (Stanford University) via Material Transfer Agreements. Cells were authenticated 
by short tandem repeat (STR) profiling (Public Health England, UK). Cells were used within 10 
passages from thawing and confirmed to be mycoplasma free (in-house testing). SF7761 and SF8628 
culture has been described previously.13 SU-DIPG IV cells were grown in tumor stem media: 
Dulbecco’s modified Eagle medium / Ham’s F-12 (DMEM/F12) and Neurobasal-A media [1:1 ratio], 
with B27 neural cell culture supplement (2%), human basic fibroblast growth factor (hFGF-basic; 20 
ng/ml; Peprotech, London, UK), mouse epidermal growth factor (mEGF; 20 ng/ml; Peprotech), human 
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platelet-derived growth factor AA (hPDGF-AA; 10 ng/ml; Generon, Maidenhead, UK), hPDGF-BB (10 
ng/ml; Generon) and heparin (2 mg/ml, StemCell Technologies, Grenoble, France). Cells were 
seeded 16 hours prior to treatment in all instances and maintained at 5% CO2 and 37°C. Cells were 
treated with drugs for 24 hours unless stated otherwise. Serially diluted stock solutions of palbociclib 
and temsirolimus were reconstituted in artificial cerebrospinal fluid (Torbay Pharmaceuticals, 
Paignton, Devon, UK) and dimethyl sulfoxide, respectively.   
Protein immunoblotting 
Immunoblotting was performed as previously described.14 Nitrocellulose membranes were 
probed overnight at 4oC with the following antibodies at their respective dilutions. From Cell Signaling 
Technology (Danvers, Massachusetts, USA): RB (4H1) #9309 1:1000; phospho-RB (Ser807/811) 
#8516 1:1000; CDK6 (D4S8S) #13331 1:500; cyclin D1 (92G2) #2978 1:500; mTOR #2972 1:1000; 
phospho-mTOR (Ser2448) #2971 1:1000; S6 kinase (49D7) #2708 1:1000; phospho-S6 kinase 
(Thr389, 108D2) #9234 1:1000; 4EBP1 (53H11) #9644 1:2000; phospho-4EBP1 (Thr37/46) #9459 
1:500; Rictor (53A4) #2114 1:1000; phospho-rictor (Thr1135, D30A3) #3806 1:1000; anti-rabbit HRP 
#7074 1:2000; and anti-mouse HRP #7076 1:1000. In addition to p16INK4A #MAB4133 (Millipore, 
Watford, UK) and CDK4 #559677 (Becton Dickinson, Wokingham, UK). Densitometry values are the 
mean of triplicate determinations and representative blots are shown.  
Cell viability assays 
Cell viability and cytotoxicity were measured with a two-color fluorescent-based live/dead kit 
(Life Technologies, Paisley, UK) utilizing calcein acetoxymethyl (calcein-AM) and ethidium 
homodimer-1 (ethD-1). Cells were seeded in 96-well plates and incubated for 16 hours prior to drug 
treatments. Cells were dosed with various concentrations of each drug, as described in the Results 
section below. Cells were then washed with phosphate-buffered saline and incubated with 2 μM 
calcein-AM and 4 μM ethD-1 for 30 minutes. Fluorescence was measured on a microplate reader 
(FLUOstar Omega; BMG Labtech, Aylesbury, UK) and normalized against appropriate controls. 
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Flow cytometry 
Cells were seeded on 12-well plates and dosed with palbociclib, temsirolimus, or both, as 
described. SF7761, SF8628 and SU-DIPG IV cells were seeded at 3.5 x 105, 0.4 x 105 and 1 x 105 
cells per well, respectively, for experiments requiring 24 hours drug treatments; and at 1 x 105, 0.2 x 
105 and 0.4 x 105 cells per well, respectively, for 72 hours experiments. Cells were then detached 
from the growing surface using Accutase solution and collected. For cell viability analysis, calcein-AM 
and ethD-1 were diluted in PBS at 1:10,000 and 1:250, respectively, prior to addition to cell 
suspensions at a 1:1 ratio. For cell cycle analyses, DRAQ5 (eBioscience, San Diego, California, USA) 
was diluted 1:200 in PBS and added to cell suspensions at a 1:1 ratio.      
Clonogenic assays 
SU-DIPG IV cells were seeded at 800 cells per 6-cm dish, 16 hours prior to treatments 
described in the text. Cells were processed as previously described.14 At the end of the experiment 
cells were fixed by addition of methanol/acetic acid (3:1) for 5 minutes, then stained with 0.5% (v/v) 
crystal violet solution (diluted in methanol) for 10 minutes. Colonies were counted using the colony 
area plugin for ImageJ (version 1.46r; National Institutes of Health, USA). 
In vitro neurotoxicity assessment via fluorescent 
immunocytochemistry 
Experiments were performed on rat E18 hippocampal cultures grown on poly-D-lysine coated 
glass coverslips after cell extraction had been performed using previously described protocols.15 
Palbociclib toxicity was assessed after 24 hours of treatment using immunocytochemistry assays 
performed on untreated and palbociclib treated primary hippocampal cells as described previously.13 
 
In vivo neurotoxicity assessment via fluorescent 
immunohistochemistry 
Targeted delivery of palbociclib to the brain striatum of Wistar rats was achieved using a 
custom cannula system and rate-controlled microinfusion pump, as previously described.15 The 
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animals used in this study were handled according to the protocols approved by the ethical committee 
of University of Bristol and all the protocols were performed in accordance with the UK Animal 
Scientific Procedures Act 1986. Immunohistochemical analysis of tissue sections was performed as 
previously described.15 Briefly, animals were transcardially perfused with 4% paraformaldehyde and 
the brains removed, then fixed using 4% paraformaldehyde. Rat brains were then cut into 35 μm thick 
sections at -20oC and mounted on microscope slides. Anti-NeuN (1:100; Millipore, Burlington, MA, 
USA) and anti-GFAP (1:300; Millipore) primary antibodies were used together with standard 
immunofluorescent protocols to identify any neuronal disruption and gliosis, respectively. 
 
Results 
Combination treatment with palbociclib and temsirolimus inhibit 
both the CDK4/6-cycD1-RB and mTORC1 signaling pathways in 
DIPG cells  
Barton et al, 2013 previously showed that palbociclib was effective at inhibiting the CDK4/6-
cycD1-RB signaling pathway at sub-micromolar concentrations in genetically engineered murine 
DIPG cells.16 Furthermore, analogues of temsirolimus, such as everolimus, have been shown to be 
effective at inhibiting cell viability at low-micromolar concentrations in non-DIPG brain malignancies, 
such as glioblastoma.17,18 Thus, in order to establish whether palbociclib and temsirolimus could be 
clinically relevant to DIPG, we initially examined their effects on the expression of key proteins in the 
CDK4/6-cycD1-RB and mTOR signaling pathways in three ex vivo human DIPG cell lines, at 
concentrations known to elicit strong on-target effects (0.5 M and 10 M, respectively).     
Heterodimeric CDK4/6-cycD complexes phosphorylate, and consequently, inhibit RB activity. 
Therefore, hypophosphorylated RB is an indicator of inhibition of CDK4/6 and release of the block on 
RB activity. We found palbociclib effectively inhibited CDK4/6 after 24 hours, eliciting marked 
decreases in the phosphorylation of RB in all three cell lines (Fig. 1), and dose-dependently across a 
range of doses in SF7761 (Fig. 2). As palbociclib is thought to have maximal activity in situations 
where RB is intact and p16INK4A is lacking, we wished to clarify that p16INK4A expression was absent in 
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our cells (although deletion of CDKN2A and a lack of p16INK4A protein expression has been shown 
previously in SF7761,19 SF862820 and SU-DIPG IV20). As our cell lines all lacked p16INK4A expression 
(Fig. S1), we suggest that in DIPG cells palbociclib acts as a proxy for the p16INK4A-mediated inhibition 
of CDK4/6, and the consequential attenuation of cell cycle progression, normally found in non-
cancerous cells.4 Furthermore, as the expression of CDK4, CDK6 and cycD1 were largely unaffected 
by palbociclib treatment, it appears more likely that the observed impact of palbociclib on cell 
proliferation resulted from its archetypal effects on CDK4/6 inhibition alone, rather than any off-target 
effects or non-specific hypertoxicity affecting the CDK4/6-cycD-RB pathway.  
In contrast, temsirolimus had a limited effect on RB activation in the cell lines tested (Fig. 1), 
and only demonstrated an effect on RB at the highest doses in SF7761 (i.e. 10-40 M; Fig. 2). 
Concurrent use of both drugs potentiated inhibition of CDK4/6 by palbociclib and enhanced RB 
activation, indicative of antiproliferative effects. Immunoblotting also revealed that the combination 
treatment produced a conspicuous decrease in CDK expression, which was not readily observable 
following single-agent treatments. This may also contribute to inhibition of cell proliferation.  
Temsirolimus is a rapamycin analogue and hence a specific inhibitor of mTOR. It binds with 
FK506-binding protein 12 (FKBP12), which then directly binds mTORC1 and obscures the correct 
alignment of substrates to its catalytic cleft; preferentially inhibiting phosphorylation of the mTOR 
substrate p70 ribosomal protein S6 kinase (S6K) over 4E-binding protein 1 (4EBP1).21 In all three cell 
lines, temsirolimus elicited a significant decrease in mTORC1 activity, indicated by decreased 
phosphorylation of mTOR and its downstream targets S6K and 4EBP1 (Fig. 1). This effect was dose-
dependent in SF7761 and no phosphorylated mTOR protein was detectable following treatment with 
20 M temsirolimus (Fig. 2). Dose-dependent reduction of cycD1 also resulted from temsirolimus 
treatment, which showed some correlation with reduced mTOR activity in the lower dose range (fold 
change at: 0.2 M = 0.65 and 0.48; 2 M = 0.38 and 0.21; 10 M = 0.33 and 0.08; 20 M = 0.17 and 
0.01; 40 M = 0.07 and 0.01 M; for cycD1 and p-mTOR/mTOR, respectively). This reflects the role 
of mTORC1 as a positive regulator of the translation of cycD1 protein,22 indicating on-target effects of 
temsirolimus in DIPG cells.  
Furthermore, palbociclib potentiated inhibition of mTORC1 by temsirolimus, with the addition 
of 0.5 M palbociclib bringing about additional significant down-regulation of mTOR, S6K and 4EBP1 
phosphorylation. Palbociclib’s augmentation of the effectiveness of temsirolimus on mTOR pathway 
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inhibition shows hallmarks of being more than just an additive effect, because when palbociclib was 
used as a single drug at this low dose it had an unremarkable effect on mTOR, S6K or 4EBP1. With 
single agent temsirolimus eliciting substantial reductions in mTOR activity, palbociclib’s potentiation of 
the direct effect of temsirolimus on mTOR was difficult to quantify, with increased effects on mTOR 
slightly observable in only one cell line (SF7761; Fig. 2). However, increased effects on mTOR 
following combination treatment were observed indirectly via increased hypophosphorylation of 
4EBP1 in all three cell lines (Fig. 1). For example, in SF7761, using 0.02 M temsirolimus in 
combination with 0.5 M palbociclib led to a fold change of 0.32 in mTOR phosphorylation, whereas 
the same dose of temsirolimus only elicited a fold change of 0.93 for the single agent treatment (Fig. 
1). Likewise, S6K and 4EBP1 showed significantly increased hypophosphorylation in SF7761 across 
a range of doses following combination treatment, as compared to temsirolimus alone (e.g. p-
S6k/S6K: fold change at 0.02 M temsirolimus = 0.90 and 0.01 for temsirolimus and temsirolimus + 
palbociclib, respectively; and p-4EBP/4EBP: fold change at 0.02 M temsirolimus = 0.97 and 0.53 for 
temsirolimus and temsirolimus + palbociclib, respectively).     
Concurrent use of temsirolimus with palbociclib also resulted in increased activation of RB, 
despite the equivalent single agent doses having minimal effects on RB phosphorylation (Fig. 1). 
Specifically, in SF7761 cells, 0.5 M PD and 0.02 M TM only elicited a fold-change in RB 
phosphorylation of 0.5 and 0.93, respectively. In combination, these doses caused a fold-change of 
0.06. Furthermore, combination treatment produced a conspicuous decrease in CDK expression, 
which was not readily observed following single agent treatments (Fig. 1). Finally, use of both drugs 
together promoted hypophosphorylation of the mTORC2-associated rictor protein (Fig. 2), signifying 
rictor activation and enhanced mTORC2 activity. As S6K is a negative regulator of rictor,23 it is 
unsurprising that the increased inhibition of S6K observed following combination treatment, stimulated 
rictor activation. However, this is an undesirable side-effect of an antitumorigenic treatment because 
increased mTORC2 activity signifies increased cell growth and proliferation. Nevertheless, 
considering the increased antiproliferative effects of the drugs in combination observed in our other 
assays (see below), we propose the concurrent use of both drugs establishes a cellular environment 
not conducive to cell expansion, thus mTORC2 activation is ineffectual.    
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CDK4/6 and mTOR inhibition decrease viability in DIPG cells 
without triggering extensive cytotoxicity 
Once we had established that palbociclib and temsirolimus had significant on-target effects on 
DIPG cells, we attempted to establish whether these molecular effects translated to significant 
inhibition of DIPG cell growth. We first measured changes in cell viability in our three DIPG cell lines 
treated with a range of concentrations of either palbociclib or temsirolimus (200 nM - 200 M). 
Following 24 hours treatment with palbociclib, cell viability was found to decrease in a dose-
dependent manner in all three cell lines (Fig. 3A). A highly significant reduction in viability was 
reached by 15 M palbociclib in all cell lines. However, significant cytotoxicity was only evident in cells 
at 25 M palbociclib (Fig. 3B). This implies a cytostatic mode of action at IC50 doses of palbociclib 
(Table 1 and Fig. S2). Similarly, temsirolimus also provoked a dose-dependent loss in cell viability in 
all three cell lines (Fig. 3C) and showed cytostatic traits. Specifically, temsirolimus elicited significant 
loss of viability in SF7761 and SU-DIPG IV following treatment with 10 M temsirolimus, whilst only 
causing substantial toxicity at 25 M (Fig. 3D); this is higher than the calculated IC50 values of 20.9 
and 16.8 M, for SF7761 and SU-DIPG IV, respectively (Table 1 and Fig. S2). In SF8628, no 
significant cytotoxicity following temsirolimus treatment was observed at any of the concentrations 
tested (Fig. 3D).   
 
 
Palbociclib and temsirolimus act synergistically to restrict the 
growth of DIPG cells  
It has been shown previously in other malignancies that overcoming CDK4/6 inhibitor 
resistance and increasing the therapeutic potency of CDK4/6 inhibitors can be achieved by combining 
this class of therapeutic with other pathway selective agents.24 As palbociclib and temsirolimus 
appeared effective at inhibiting DIPG cell growth as monotherapies, we next assessed the effect of 
the drugs in combination on cell viability. To achieve this, we treated cells with a variable 
concentration of temsirolimus (200 nM-200 M) in combination with a single fixed dose of palbociclib 
for 24 hours (either 0, 2, 10, 12, 15 or 25 M). Combination treatments demonstrated that the two 
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drugs worked effectively in combination and increasing the concentration of the fixed dose of 
palbociclib triggered greater reductions in cell viability (Fig. 4). Quantitative assessment of synergy 
generated combination indices that were indicative of additive or synergistic effects. For example, in 
SF7761 and SF8628 cells a 15 M fixed dose of palbociclib yielded highly synergistic combinations 
with various doses of temsirolimus, exclusively producing combination index values <1, most lying 
between 0.3 and 0.7, consistent with ‘true synergism’.25 In experiments involving SU-DIPG IV, a lower 
dose of 10 M palbociclib was sufficient to bring about strong synergistic effects on cell viability.     
A more detailed examination of cell viability using flow cytometry (Fig. 5) supported our initial 
findings, whilst also indicating that although palbociclib caused only limited cell death at lower doses, 
cell numbers generally decreased steadily; below the percentage of live cells in all instances (Fig. 5, 
left panels). Doses of palbociclib above 25 M appeared to be highly toxic, causing considerable cell 
death, consistent with our initial cytotoxicity assays (Fig. 3B). Thus, palbociclib doses of this 
magnitude appeared fundamentally cytotoxic and were excluded from the experiments that followed. 
Cytostatic-driven reductions in cell viability were more evident in cells treated with temsirolimus. In 
SF7761 and SF8628 temsirolimus produced negligible cell death at all concentrations up to 50 M, 
whilst cell numbers consistently decreased in a dose-dependent manner relative to untreated cells 
(Fig. 5, center panels). Coadministration of a low fixed dose of palbociclib (either 15 M for SF7761 
and SF8628, or 10 M for SU-DIPG IV cells), combined with varying concentrations of temsirolimus 
potentiated the effects on cells (Fig. 5, right panels), provoking a significant decrease in the number of 
cells, together with cell viability (particularly in SF7761 and SU-DIPG IV). Implying a shift from a 
cytostatic to cytotoxic mode of action, indicative of increased anti-tumorigenic properties. These 
doses of palbociclib were chosen as they were close to the drug’s IC50 and also elicited strong 
synergism with temsirolimus (established in the previous experiments above), while they were also 
largely sub-lethal in the single drug flow cytometric analyses.   
 
Combined CDK4/6 and mTOR inhibition cytostatically inhibit 
proliferation and trigger G0-G1 cell cycle arrest  
Having observed that the combination of palbociclib and temsirolimus potentiated each drug’s 
cytostatic effects, we next investigated whether these effects continued beyond the initial 24-hour 
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time-period. Low, sub-lethal doses of each drug were selected based on the previous data, as well as 
cell line-specific drug sensitivity and some preliminary experiments examining the effects of the drugs 
over time (data not shown). These criteria led to us utilizing a dose of 2 M palbociclib for all three cell 
lines, as this drug concentration had no effect on cell death in any of the three cell lines, and only a 
very limited effect on cell proliferation in SF8628 and SU-DIPG IV. A concentration of 10 M 
temsirolimus was utilized for SF7761 and SF8628, while a lower dose of 0.2 M temsirolimus was 
used for SU-DIPG IV, as this cell line was more sensitive than the other cell lines to temsirolimus, and 
showed significant loss of viability at 10 M in the previous flow cytometric analyses. Throughout the 
72 hours viability in control cells remained high (Fig. 6A-C, left). Similarly, treatment with either 
palbociclib or temsirolimus did not impact on cell viability. However, cells treated with palbociclib or 
temsirolimus clearly demonstrated diminished proliferation, which intensified over time (Fig. 6A-C, 
center and right, respectively).  
Effects on cell proliferation were investigated further via cell cycle analyses. In SF7761 cells, 
treatment with palbociclib and temsirolimus for 24 hours caused a marked increase in the percentage 
of cells in the G0-G1 phase of the cell cycle, consistent with CDK4/6 inhibition and mTOR inhibition, 
respectively (Fig. 7A). G0-G1 arrest persisted over 72 hours in all three cell lines tested, with SU-DIPG 
IV demonstrating the greatest amount of cell cycle arrest (Fig. 7B, 7C and S3). To further assess the 
antiproliferative effects of the drugs, we performed clonogenic assays using SU-DIPG IV cells, which 
unlike SF7761 and SF8628, exhibit strong intrinsic clonogenicity. We found palbociclib and 
temsirolimus inhibited colony formation time-dependently as single agents, and concurrent treatment 
with both drugs potentiated the effect of temsirolimus at all three time points (Fig. 7D and S4). The 
clonogenicity of SU-DIPG IV showed very high sensitivity to palbociclib in our preliminary combination 
experiments, and thus a dose of 0.5 M palbociclib (in line with our initial immunoblotting assays) was 
used in combination with temsirolimus, which was sufficient to considerably augment the ability of 
temsirolimus to reduce colony numbers. Taken together these data suggest the drugs provided 
sustained antiproliferative effects, via cell cycle arrest.     
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Palbociclib does not cause significant neurotoxicity in normal brain 
tissue 
It has previously been demonstrated that the lipophilic nature of temsirolimus enables it to 
readily cross the blood-brain barrier (BBB).11 In contrast, palbociclib does not readily cross the BBB.26 
To address this issue, we propose it would be prudent to deliver palbociclib directly into the brain of 
DIPG patients to circumvent the BBB, while temsirolimus could be infused intravenously, which does 
not pose any known toxicity issues.12 With this in mind, we examined the effect of palbociclib on 
normal brain tissue. To achieve this, we initially exposed normal neurons and glial cells within primary 
rat hippocampal cultures to 2 M palbociclib  and observed no discernable toxic effects, relative to the 
general morphology and numbers of cells seen in vehicle-treated cultures (Fig. 8). We went on to 
investigate the toxicity of palbociclib in vivo by carrying out direct infusions of either 100 M or 400 M 
palbociclib into the striatum of normal rat brains. Analyses of the brain tissue showed no significant 
neurotoxicity caused by palbociclib, as compared to control animals (Fig. 9).       
   
Discussion 
DIPG is a highly heterogeneous disease characterized by lethal tumors that differ in cellular 
origin and pathogenesis. In part, this heterogeneity is derived from the genetic basis of the disease 
and two archetypal causative mutations.27,28 In the present study we have shown that palbociclib and 
temsirolimus can reduce DIPG cell proliferation in vitro in three different cell lines encompassing the 
two histone H3 mutations most frequently associated with DIPG (H3.3K27M represented by SF7761 
and SF8628; and H3.1K27M in SU-DIPG IV). On the whole we found that palbociclib and 
temsirolimus was more efficacious in SU-DIPG IV cells; suggesting that DIPG tumors harboring the 
H3.1K27M mutation may be more suited to the proposed drug combination. Though SF7761 and 
SF8628 cells both harbor the H3.3K27M mutation, SF7761 was generally more sensitive to drug 
treatments. This variation in the two H3.3K27M cell lines likely relates to other genotypic differences, 
and phenotypic differences, that exist between these cells. Crucially, the SF7761 cell line has been 
modified to express telomerase, whereas SF8628 is unmodified and has been established directly 
from DIPG biopsy. Consequently, SF7761 cells can potentially survive indefinitely in vitro, whereas 
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SF8628 cells senesce over time. Furthermore, SF7761 have a shorter doubling time compared to 
SF8628 (Fig. 6), are typically much smaller cells and are cultured in a different culture media 
formulation. These cell lines have also been shown to have distinctive endogenous genetic profiles 
beyond the shared H3 histone mutation. For example, expression of the nuclear kinase WEE1 is 
much higher in SF8628 compared to SF7761.29 Asymmetrical expression of this important cell cycle 
regulator could conceivably contribute to the dissimilar response to our proposed novel drug 
combination, which specifically targets cell cycle arrest. Irrespective of these differences, the 
combination of palbociclib and temsirolimus brought about strong growth inhibition in both SF7761 
and SF8628.                        
While many novel DIPG therapeutics have been proposed in recent years, none have been 
successfully implemented.30, 31 Single-agent rapalogue treatments for CNS tumors, including DIPG, 
have had limited success.32-36 However, temsirolimus has been well tolerated in pediatric patients.12 
The situation is similar for CDK4/6 inhibitors, where use of these drugs as robust single-agent 
treatments for different cancers has proven unconvincing.32, 38-40 Nevertheless palbociclib has been 
well tolerated, increased survival in a DIPG mouse model16 and can elicit anti-tumor immunological 
effects.41 Both rapalogues and CDK4/6 inhibitors have shown tolerability in the CNS, but have 
produced mixed results for treating CNS tumors.3,7,12,23  
Palbociclib has strong potential utility for treating DIPG, because RB disruption is uncommon 
in DIPG and cells typically lack functional p16INK4A; key prerequisites for palbociclib efficacy. 
Furthermore, p16INK4A has been shown to be repressed by aberrant histone H3.3K27M expression, 
which is a common mutation in DIPG.26,42 Rapalogues also have intrinsic potential for treating DIPG 
and can be used to overcome the characteristic hyperactivated PI3K/AKT/mTOR signaling exhibited 
in DIPG cells.37 For example platelet-derived growth factor receptor (PDGFR) is commonly 
overexpressed in DIPG and drives cancer cell proliferation via the PI3K/AKT/mTOR signaling 
pathway. Combining rapalogues with CDK4/6 inhibitors has proven effective previously,4,18 and in 
accord with other groups, we found that palbociclib potentiates the effects of temsirolimus and may 
facilitate circumvention of its downstream repression by AKT. We propose palbociclib negates 
intrinsic CDK4-cycD1 complex inhibition of tuberous sclerosis complex 2,41 thus increasing mTORC1 
inhibition and sensitization to temsirolimus. Furthermore, the decreased cycD1 and CDK4/6 
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expression, along with augmented hypophosphorylation of RB observed following our combination 
treatments, would serve to decrease mTOR activity further within this paradigm.  
In addition to palbociclib potentially supplementing the effects of temsirolimus, temsirolimus 
may also potentiate palbociclib. Documented undesirable effects that have curtailed interest in 
palbociclib as a cancer treatment, such as attenuation of its own antimitogenic effects through 
increased cellular metabolism, can be abrogated by mTOR inhibition.24 This was observed in our 
experiments via enhanced RB activation. We hypothesize this may arise through the capacity of 
temsirolimus to block global pro-mitogenic cellular effects caused by palbociclib (as described above), 
in addition to a blockade of cycD1 expression, which is positively-regulated by mTOR and would 
hence be restricted by temsirolimus. With a cycD1 deficit, there would be a propensity for further 
restriction of CDK4/6-cycD1 complex formation and hence decreased RB phosphorylation. 
Interestingly, if CDK4/6-cycD1 complexes form part of the mTOR regulation machinery in DIPG cells, 
and palbociclib and temsirolimus synergize to drive a significant deficit of cycD1, then ultimately a 
negative feedback loop would ensue, whereby decreased cycD1 expression intensifies mTOR 
inhibition, and mTOR inhibition decreases cycD1 expression. Thus, palbociclib and temsirolimus 
potentially elicit an antimitogenic positive feedback loop when used concurrently, with palbociclib 
inducing rapalogue sensitization, and temsirolimus inhibiting the negative side-effects of palbociclib. 
We propose that pathway cross-regulation and mutual potentiation of the inhibition of target proteins, 
drives increased antiproliferative effects and the observed shift towards cytotoxicity in cancer cells.  
Despite advocating that palbociclib potentiates the inhibitory effects of temsirolimus on mTOR 
and facilitates circumvention of AKT-driven restoration of mTORC1 activity, we also observed that 
concurrent use of palbociclib and temsirolimus increased activation of the mTORC2-associated rictor 
protein. This did not however appear to affect cell viability. This may in part be due to the relatively 
short 24-hour exposure time for most of our drug treatments, chosen principally to mimic patient drug 
infusion times, but which also illustrated rapid drug efficacy. Furthermore, where longer treatment 
times were used (i.e. Fig. 6 and 7), pro-mitogenic mTORC2 effects did not appear significant and cell 
proliferation continued to decline. We are unable to fully rationalize this discrepancy and intend further 
investigation, but suggest temsirolimus may directly inhibit mTORC2 in DIPG cells. Rapalogues have 
been found to have an inhibitory effect on mTORC2 in some cancer cells, dependent on high 
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expression of FKBP12.43 Pertinently, FKBP12 is significantly overexpressed in childhood 
astrocytomas.44 
 
Conclusion 
Taken together, our results support the notion that the best clinical potential for developing an 
efficacious DIPG therapeutic will stem from concurrent inhibition of multiple oncogenic pathways. Our 
data suggest palbociclib and temsirolimus synergistically reduce cell viability in SF7761, SF8628 and 
SU-DIPG IV cells primarily through increased cytostatic effects that drive down cell proliferation, with 
some cytotoxicity likely stemming from the loss of metabolic compensatory pathways. As this project 
is principally an in vitro study, further investigation is required to translate these findings to the clinical 
setting. Frequently, treatment failures occur because agents cannot cross the blood–brain barrier due 
to efflux transporters. The ability of palbociclib to sufficiently enter the brain remains a concern,26 but 
mTOR inhibitors have been shown to ameliorate palbociclib efflux and facilitate increased drug 
concentrations in the CNS.18,45 Nevertheless, our results demonstrate that simultaneous inhibition of 
the CDK4/6-cycD1-RB and PI3K-AKT-mTOR pathways is a feasible approach to DIPG treatment. 
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Figure 1 CDK4/6 and mTOR inhibitors cross-regulate, leading to enhanced inhibition of the 
respective pathways when used in combination.  
Notes: SF7761, SF8628 and SU-DIPG IV cells were treated with either vehicle, 0.5 M palbociclib, 
10 M temsirolimus or coadministered of 0.5 M palbociclib with 10 M temsirolimus for 24 hours 
prior to total protein extraction and immunoblot analyses. Quantitative densitometry values are shown 
below each blot. Densitometry graphs compare single-agent treatments and combination treatment to 
vehicle treated controls (right). -actin was used as a loading control. Data are the mean ± SEM of 
triplicate determinations in all instances. *, p < 0.05; **, p < 0.01; ***, p < 0.001 (compared to 
respective vehicle treatment). #, p < 0.05; ##, p < 0.01; ###, p < 0.001 (compared to respective 
temsirolimus single-agent treatment).  
Abbreviations: RB, retinoblastoma protein; CDK, cyclin-dependent kinase; mTOR, mechanistic 
target of rapamycin protein; S6K, p70 ribosomal protein S6 kinase; 4EBP1, eukaryotic translation 
initiation factor 4E-binding protein 1; rictor, rapamycin-insensitive companion of mammalian target of 
rapamycin; p-, phosphorylated form of protein.   
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Figure 2 Coadministration of palbociclib with temsirolimus yields beneficial enhancement of CDK4/6 
and mTOR inhibition in DIPG cells. 
Notes: SF7761 cells were treated with a range of doses of palbociclib, temsirolimus or temsirolimus 
coadministered with 0.5 M palbociclib for 24 hours prior to total protein extraction. Immunoblot 
analyses showed palbociclib and temsirolimus effectively inhibited CDK4/6-cycD1-RB and mTOR 
signaling pathways in DIPG cells, respectively, while each drug also exhibits inherent attributes to 
disrupt the other's target protein, leading to an ostensible synergistic outcome when used in 
combination. Quantitative densitometry values are shown below each blot. Densitometry graphs 
compare single-agent temsirolimus treatment and temsirolimus given in combination with 0.5 M 
palbociclib (right). Dotted line emphasizes 0.5 M palbociclib single-agent results versus combination 
effects. -actin was used as a loading control. Data are the mean ± SEM of triplicate determinations in 
all cases. #, p < 0.05; ##, p < 0.01; ###, p < 0.001 (compared to respective temsirolimus single-agent 
treatment).  
Abbreviations: RB, retinoblastoma protein; CDK, cyclin-dependent kinase; mTOR, mechanistic 
target of rapamycin protein; S6K, p70 ribosomal protein S6 kinase; 4EBP1, eukaryotic translation 
initiation factor 4E-binding protein 1; rictor, rapamycin-insensitive companion of mammalian target of 
rapamycin; p-, phosphorylated form of protein. PD, palbociclib; TM, temsirolimus.   
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Figure 3 Palbociclib and temsirolimus treatments as monotherapies reduce cell viability in DIPG. 
Notes: A, calcein-AM cell viability assays were performed on SF7761, SF8628 and SU-DIPG-IV 
DIPG cell lines treated with increasing concentrations of palbociclib for 24 hours. B, drug cytotoxicity 
was measured following 24 hours treatment with palbociclib, using ethidium homodimer-1 (ethD-1). C, 
cell viability assays were performed on SF7761, SF8628 and SU-DIPG IV cell lines treated with 
increasing concentrations of temsirolimus for 24 hours. D, drug cytotoxicity was measured following 
24 hours treatment with temsirolimus, using ethD-1. Data are the mean ± SEM of triplicate 
determinations. *, p < 0.05; **, p < 0.01; and ***, p < 0.001 (compared to the respective vehicle 
treatment). 
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Figure 4 Coadministration of palbociclib and temsirolimus decreases cell viability synergistically. 
Notes: SF7761 (A), SF8628 (B) and SU-DIPG IV (C) cells were treated with single-agent 
temsirolimus at increasing concentrations (0.2-200 M) or the same concentration range combined 
with a single fixed dose of palbociclib (either 2, 10, 12, 15 or 25 M). Cell viability was assessed using 
calcein-AM staining. A combination index score was assigned to each of the different combinations 
and is shown on the right. Data are the mean ± SEM of triplicate determinations. 
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Figure 5 Coadministration of palbociclib and temsirolimus decreases cell viability principally through 
restricting cell proliferation.  
Notes: Bivariate flow cytometric analyses of cell viability in SF7761 (A), SF8628 (B) and SU-DIPG IV 
(C) cells. Cells were treated with palbociclib (0–50 mM), temsirolimus (0–50 mM) or both 
(temsirolimus 0–50 mM, with a fixed dose of either 10 mM or 15 mM palbociclib, dependent on cell 
line sensitivity). Analysis of “% live cells” (calcein-AM positive), “% dead cells” (ethD-1 positive) and 
“% dying cells” (double positive) was performed. The dotted line box in each of the panels on the left-
hand side emphasizes the dose of palbociclib used for the combinatorial analyses. Data are the mean 
± SEM of triplicate determinations. 
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Figure 6 Palbociclib and temsirolimus inhibit the growth of DIPG cells cytostatically.  
Notes: SF7761 (A), SF8628 (B) and SU-DIPG IV (C) cells were treated with vehicle, palbociclib (2 
M) or temsirolimus (10 M for SF7761 and SF8628; 0.2 M for SU-DIPG IV) for 0-72 hours. Cells 
were then counted and stained with calcein-AM to deduce % viability, via flow cytometry. Data are the 
mean ± SEM of triplicate determinations in all cases.  
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Figure 7 Palbociclib and temsirolimus treatments lead to cell cycle arrest. 
Notes: A, DRAQ5 fluorescent dye was used to perform flow cytometric cell cycle analysis on SF7761 
cells treated with either vehicle, 2 M palbociclib or 10 M temsirolimus for 24 hours. B, DRAQ5 cell 
cycle analysis of SF7761, SF8628 and SU-DIPG IV cells treated with 2 M palbociclib demonstrated 
a significant increase in the percentage of cells in the G0-G1 phase over time. C, DRAQ5 cell cycle 
analysis of SF7761 and SF8628 cells treated with 10 M temsirolimus, and SU-DIPG IV cells treated 
with 0.2 M temsirolimus demonstrated a significant increase in the percentage of cells in the G0-G1 
phase over time. D, SU-DIPG IV cells were treated with temsirolimus, or the combination of 
temsirolimus and 0.5 M palbociclib for 24-72 hours, and colonies counted after 14 days. 
Representative plates following 72 hours treatment are shown (right). Data are the mean ± SEM of 
triplicate determinations in all cases. *, p < 0.05; **, p < 0.01; and ***, p < 0.001 (compared to 
respective vehicle treatment). 
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Figure 8 Treatment of rat hippocampal primary cultures with palbociclib did not elicit cytotoxicity. 
Notes: Primary hippocampal culture treated with vehicle solution or 2 M palbociclib for 24 hours. 
Intact neuronal networks and normal glial cell morphology was observed in cultures treated with 
palbociclib, suggesting no significant toxicity. Cell nuclei were stained with DAPI (blue); neurons were 
stained with B3 tubulin antibody (green); glial cells were stained with GFAP antibody (red/orange).  
Abbreviations: DAPI, 4',6-diamidino-2-phenylindole; B3 tubulin, tubulin, beta III isoform; GFAP, glial 
fibrillary acidic protein. 
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Figure 9 Direct delivery of palbociclib into rat brain did not elicit discernible toxicity.  
Notes: Palbociclib was infused into the striatum of rat brains at a rate of 1l / min (5 l total) at either 
100 M or 400 M. Tissue was harvested after 48 hours and analyzed using immunofluorescence 
staining. Tissue morphology appeared normal in rats dosed with palbociclib, suggesting no significant 
toxicity. Cell nuclei were stained with DAPI (blue); neurons were stained with NeuN antibody (green); 
glial cells were stained with GFAP antibody (red).  
Abbreviations: DAPI, 4',6-diamidino-2-phenylindole; NeuN, neuronal nuclear protein; GFAP, glial 
fibrillary acidic protein. 
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Table 1 IC50 values for 24 hours single-agent and combination treatments in SF7761, SF8628 and 
SU-DIPG IV cells 
 
Drug treatment 
IC50 (μM) 
SF7761 
IC50 (μM) 
SF8628 
IC50 (μM) 
SU-DIPG IV 
Palbociclib (0.2-200 M) 16.55 16.50 8.77 
Temsirolimus (0.2-200 M) 20.88 36.62 16.83 
Temsirolimus (0.2-200 M) + 2 M Palbociclib - - 11.52 
Temsirolimus (0.2-200 M) + 10 M Palbociclib 15.83 24.95 0.16 
Temsirolimus (0.2-200 M) + 12 M Palbociclib 4.82 - 0.002 
Temsirolimus (0.2-200 M) + 15 M Palbociclib 0.89 2.03 0.002 
Temsirolimus (0.2-200 M) + 20 M Palbociclib - 0.001 - 
Temsirolimus (0.2-200 M) + 25 M Palbociclib 0.44 - - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
